Udvalget for Humanmedicinske Lægemidler (CHMP) har konkluderet, at Baraclude er påvist at være mere effektivt end den nuværende behandling af infektioner med hepatitis B- virus.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Baraclude had shown that it was as or more effective than the current treatment for hepatitis B virus infections.